{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:29:37Z","timestamp":1790188177695,"version":"4.1.0"},"reference-count":20,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2018,12,1]]},"DOI":"10.1001\/jamaoncol.2018.3277","type":"journal-article","created":{"date-parts":[[2018,9,3]],"date-time":"2018-09-03T22:35:54Z","timestamp":1536014154000},"page":"1707","source":"Crossref","is-referenced-by-count":114,"title":["Nab-Paclitaxel and Gemcitabine as First-line Treatment of Advanced or Metastatic Cholangiocarcinoma"],"prefix":"10.1001","volume":"4","author":[{"given":"Vaibhav","family":"Sahai","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Catalano","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark M.","family":"Zalupski","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam Joseph","family":"Lubner","sequence":"additional","affiliation":[{"name":"University of Wisconsin Carbone Cancer Center, Madison"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark R.","family":"Menge","sequence":"additional","affiliation":[{"name":"Frauenshuh Cancer Center, Park Nicollet Health Services, Minneapolis, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halla Sayed","family":"Nimeiri","sequence":"additional","affiliation":[{"name":"Robert H. Lurie Cancer Center of Northwestern University, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidayatullah G.","family":"Munshi","sequence":"additional","affiliation":[{"name":"Robert H. Lurie Cancer Center of Northwestern University, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Al Bowen","family":"Benson","sequence":"additional","affiliation":[{"name":"Robert H. Lurie Cancer Center of Northwestern University, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"O\u2019Dwyer","sequence":"additional","affiliation":[{"name":"Abramson Cancer Center, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"1","key":"coi180063r1","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.cgh.2012.09.009","article-title":"Classification, diagnosis, and management of cholangiocarcinoma.","volume":"11","author":"Razumilava","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"14","key":"coi180063r2","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"issue":"11","key":"coi180063r3","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1007\/s11605-007-0282-0","article-title":"Trends in survival after surgery for cholangiocarcinoma: a 30-year population-based SEER database analysis.","volume":"11","author":"Nathan","year":"2007","journal-title":"J Gastrointest Surg"},{"issue":"8","key":"coi180063r4","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/S1470-2045(14)70212-8","article-title":"Gemcitabine and Oxaliplatin With or Without Cetuximab in Advanced Biliary-Tract Cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial.","volume":"15","author":"Malka","year":"2014","journal-title":"Lancet Oncol"},{"issue":"3","key":"coi180063r5","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1158\/2159-8290.CD-11-0242","article-title":"nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer.","volume":"2","author":"Frese","year":"2012","journal-title":"Cancer Discov"},{"issue":"10","key":"coi180063r6","doi-asserted-by":"publisher","first-page":"2833","DOI":"10.1007\/s11095-012-0775-8","article-title":"Meta-analysis of nanoparticulate paclitaxel delivery system pharmacokinetics and model prediction of associated neutropenia.","volume":"29","author":"Ait-Oudhia","year":"2012","journal-title":"Pharm Res"},{"issue":"1","key":"coi180063r7","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1200\/JCO.1995.13.1.180","article-title":"Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic\/pharmacodynamic relationships in humans.","volume":"13","author":"Gianni","year":"1995","journal-title":"J Clin Oncol"},{"issue":"31","key":"coi180063r8","doi-asserted-by":"publisher","first-page":"7794","DOI":"10.1200\/JCO.2005.04.937","article-title":"Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer.","volume":"23","author":"Gradishar","year":"2005","journal-title":"J Clin Oncol"},{"issue":"7","key":"coi180063r9","doi-asserted-by":"publisher","first-page":"281","DOI":"10.4251\/wjgo.v9.i7.281","article-title":"Evolving treatment landscape for early and advanced pancreatic cancer.","volume":"9","author":"Lau","year":"2017","journal-title":"World J Gastrointest Oncol"},{"issue":"18","key":"coi180063r10","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N Engl J Med"},{"issue":"34","key":"coi180063r11","doi-asserted-by":"publisher","first-page":"4548","DOI":"10.1200\/JCO.2011.36.5742","article-title":"Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I\/II trial.","volume":"29","author":"Von Hoff","year":"2011","journal-title":"J Clin Oncol"},{"issue":"2","key":"coi180063r13","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1097\/SLA.0b013e3182536a42","article-title":"Human equilibrative nucleoside transporter 1 expression predicts survival of advanced cholangiocarcinoma patients treated with gemcitabine-based adjuvant chemotherapy after surgical resection.","volume":"256","author":"Kobayashi","year":"2012","journal-title":"Ann Surg"},{"issue":"3","key":"coi180063r14","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1200\/JCO.2006.07.8824","article-title":"Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma.","volume":"25","author":"Infante","year":"2007","journal-title":"J Clin Oncol"},{"issue":"2","key":"coi180063r16","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"11","key":"coi180063r17","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1016\/j.ejca.2015.04.011","article-title":"Decline in CA19-9 during chemotherapy predicts survival in four independent cohorts of patients with inoperable bile duct cancer.","volume":"51","author":"Grunnet","year":"2015","journal-title":"Eur J Cancer"},{"issue":"6","key":"coi180063r18","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1002\/(ISSN)1097-0142","article-title":"Expanded phase II trial of gemcitabine and capecitabine for advanced biliary cancer.","volume":"110","author":"Riechelmann","year":"2007","journal-title":"Cancer"},{"issue":"3","key":"coi180063r19","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.21873\/anticanres","article-title":"Multicenter phase II clinical trial of Genexol-PM\u00ae with gemcitabine in advanced biliary tract cancer.","volume":"37","author":"Kim","year":"2017","journal-title":"Anticancer Res"},{"issue":"15","key":"coi180063r20","doi-asserted-by":"publisher","first-page":"4018","DOI":"10.1200\/JCO.2017.35.15_suppl.4018","article-title":"A phase II trial of gemcitabine (G), cisplatin (C), and nab-paclitaxel (N) in advanced biliary tract cancers (aBTCs)","volume":"35","author":"Shroff","year":"2017","journal-title":"J Clin Oncol"},{"key":"coi180063r12","unstructured":"World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.JAMA. 2013;310(20):2191-2194. doi:10.1001\/jama.2013.28105"},{"key":"coi180063r15","unstructured":"US Department of Health and Human Services Food and Drug Administration; Center for Drug Evaluation and Research; Center for Biologics Evaluation and Research. Guidance for industry: clinical trial endpoints for the approval of cancer drugs and biologics. https:\/\/www.fda.gov\/downloads\/Drugs\/Guidances\/ucm071590.pdf. Published May 2007. Accessed July 13, 2018."}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2698042","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,12,13]],"date-time":"2018-12-13T17:11:12Z","timestamp":1544721072000},"score":1,"resource":{"primary":{"URL":"http:\/\/oncology.jamanetwork.com\/article.aspx?doi=10.1001\/jamaoncol.2018.3277"}},"subtitle":["A Phase 2 Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2018,12,1]]},"references-count":20,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2018.3277","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12,1]]}}}